Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

258 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.
Mead GM, Sydes MR, Walewski J, Grigg A, Hatton CS, Pescosta N, Guarnaccia C, Lewis MS, McKendrick J, Stenning SP, Wright D; UKLG LY06 collaborators. Mead GM, et al. Among authors: sydes mr. Ann Oncol. 2002 Aug;13(8):1264-74. doi: 10.1093/annonc/mdf253. Ann Oncol. 2002. PMID: 12181251 Free article. Clinical Trial.
Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519).
Johnson PW, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS, MacLennan KA, Stenning SP, Clawson S, Smith P, Ryder D, Hancock BW; United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). Johnson PW, et al. Among authors: sydes mr. J Clin Oncol. 2005 Dec 20;23(36):9208-18. doi: 10.1200/JCO.2005.03.2151. Epub 2005 Nov 28. J Clin Oncol. 2005. PMID: 16314615 Clinical Trial.
Comparison of outcomes in studies of advanced Hodgkin's lymphoma.
Johnson PW, Radford JA, Cullen MH, Sydes MR, Stenning SP, Hancock BW. Johnson PW, et al. Among authors: sydes mr. J Clin Oncol. 2006 Jul 10;24(20):3309; author reply 3309-10. doi: 10.1200/JCO.2006.06.2976. J Clin Oncol. 2006. PMID: 16829655 No abstract available.
Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials.
Whelan JS, Jinks RC, McTiernan A, Sydes MR, Hook JM, Trani L, Uscinska B, Bramwell V, Lewis IJ, Nooij MA, van Glabbeke M, Grimer RJ, Hogendoorn PC, Taminiau AH, Gelderblom H. Whelan JS, et al. Among authors: sydes mr. Ann Oncol. 2012 Jun;23(6):1607-16. doi: 10.1093/annonc/mdr491. Epub 2011 Oct 19. Ann Oncol. 2012. PMID: 22015453 Free PMC article.
Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup.
McTiernan A, Jinks RC, Sydes MR, Uscinska B, Hook JM, van Glabbeke M, Bramwell V, Lewis IJ, Taminiau AH, Nooij MA, Hogendoorn PC, Gelderblom H, Whelan JS. McTiernan A, et al. Among authors: sydes mr. Eur J Cancer. 2012 Mar;48(5):703-12. doi: 10.1016/j.ejca.2011.09.012. Epub 2011 Oct 27. Eur J Cancer. 2012. PMID: 22036088 Free PMC article. Clinical Trial.
258 results